کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2408556 1103180 2007 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Perspectives on the development of a therapeutic HER-2 cancer vaccine
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی ایمونولوژی
پیش نمایش صفحه اول مقاله
Perspectives on the development of a therapeutic HER-2 cancer vaccine
چکیده انگلیسی

With good reason, the majority of cancer vaccines tested, or being tested, have targeted the induction of anti-tumour CTL responses. However, the clinical success of monoclonal antibodies such as Rituximab/CD20, Trastuzumab/HER-2, Cetuximab/EGFR and Bevacisumab/VEGF suggests that their respective targets may also be relevant for cancer vaccines aiming at the induction of an effective humoral anti-tumour response to mimic, or potentially improve upon, the effects of monoclonal therapies. We report here an overview of the development of a protein vaccine targeting HER-2/neu, with an emphasis on the immunologic results obtained from the testing of the vaccine in animal models of disease and in toxicology programs, to its evaluation in three clinical trials in breast cancer patients.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 25, Supplement 2, 27 September 2007, Pages B17–B23
نویسندگان
, ,